Insight on the necessary careful selection of patients with HFmrEF/HFpEF to those who are most likely to benefit from mineralocorticoid receptor antagonists. You can read the full manuscript at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.2801.